Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

inflammatory response

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2016

1

2017

1

2019

1

2020

1

2021

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Immune system diseases

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Nucleic Acid

4

Chemical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

DAILYMED

5

DRUG BANK

5

FDA ORPHAN DRUG

5

FDA UNII

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

MUSCULO-SKELETAL SYSTEM

1

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CORTICOSTEROIDS FOR SYSTEMIC USE

1

OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN

1

OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Glucocorticoids

1

Other drugs for disorders of the musculo-skeletal system

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

4

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated/Approved|Treatment of Duchenne Muscular Dystrophy." in comments (approximate match)

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CASIMERSEN

X8UHF7SX0R

Export Data
Sequence Search

Status:

US Approved Rx (2021)

First approved in 2021

Class:

NUCLEIC ACID

VILTOLARSEN

SXA7YP6EKX

Export Data
Sequence Search

Status:

US Approved Rx (2020)

First approved in 2020

Class:

NUCLEIC ACID

GOLODIRSEN

033072U4MZ

Export Data
Sequence Search

Status:

US Approved Rx (2019)

First approved in 2019

Class:

NUCLEIC ACID

ETEPLIRSEN

AIW6036FAS

Export Data
Sequence Search

Status:

US Approved Rx (2016)

First approved in 2016

Class:

NUCLEIC ACID

DEFLAZACORT

KR5YZ6AE4B

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

inflammatory response

Conditions:

Immune system diseases

Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by s...

uppressing inflammatory response.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1